{"id":22599,"date":"2026-07-16T11:22:59","date_gmt":"2026-07-16T15:22:59","guid":{"rendered":"https:\/\/greenspacehealth.com\/en-ca\/?p=22599"},"modified":"2026-07-16T11:22:59","modified_gmt":"2026-07-16T15:22:59","slug":"cms-depression-screening-star-ratings-what-health-plans-need-to-know","status":"publish","type":"post","link":"https:\/\/greenspacehealth.com\/en-ca\/cms-depression-screening-star-ratings-what-health-plans-need-to-know\/","title":{"rendered":"CMS Depression Screening Star Ratings: What Health Plans Need to Know"},"content":{"rendered":"

Between 2019 and 2023, there was a 57.4% spike in mental health diagnoses<\/a> among adults 65 and older. Today, an estimated 1 in 6 adults over 65<\/a> will experience clinically significant symptoms of depression, and yet two-thirds of older adults<\/a> with mental health problems will never receive the treatment they need. For Medicare Advantage plans, that gap is about to become a performance liability.<\/p>\n

The Centers for Medicare & Medicaid Services (CMS) is advancing a new Depression Screening and Follow-Up (DSF) measure, to be incorporated into the 2029 Star Ratings based on performance beginning with Contract Year 2027<\/a>. The measure is designed to improve identification and timely treatment of depression among older adults and, for health plans operating at scale, executing on it effectively presents a complex operational challenge.<\/p>\n

Most plans today rely on provider visits, annual wellness assessments, and health risk assessments to capture depression screening data. That approach reaches only a fraction of eligible members and leaves large portions of the population unscreened. Under the new measure, how plans address their DSF gap will have a meaningful impact on Star performance, and those who move early stand to gain a significant advantage.<\/p>\n

\n

\u2713<\/span><\/p>\n

Why it matters:<\/strong> A one-star improvement in Medicare Advantage ratings can increase a plan’s revenue by tens to hundreds of millions of dollars<\/a> annually through CMS quality bonus payments. DSF represents an outsized opportunity for plans that get it right and perform at a high level from the start.<\/p>\n<\/div>\n

To succeed, health plans will need a scalable way to identify, engage, screen, and support members within and outside of traditional care settings. This is where population health technology plays a decisive role.<\/p>\n

The DSF Display Period Is a Strategic Window<\/strong><\/h3>\n

The DSF measure is currently in its display period, which means performance is being tracked before it officially impacts Star Ratings.<\/p>\n

This means that by the time a new measure formally enters Star Ratings, high-performing plans have already built a competitive advantage because they began perfecting their strategy while it was still on display. Leading plans are using this window to understand completion and outcome trends in their population, dig into eligibility and exclusion specifications, test and refine interventions, and identify operational gaps before performance counts.<\/p>\n

With the CY2027 measurement year approaching, we’re in that window now. Plans that act today can build and optimize their screening and follow-up workflows to ensure they perform when it matters most.<\/p>\n

<\/a>Understanding the New CMS Depression Screening Measure<\/strong><\/h2>\n

The proposed measure includes two equally weighted components:<\/p>\n

1. Depression Screening Rate<\/strong><\/p>\n

The first component measures the percentage of eligible Medicare Advantage members who complete a validated depression screening assessment. CMS accepts a range of standardized instruments, with the PHQ-2<\/strong> and PHQ-9<\/strong> being the most commonly used. The PHQ-2 as a brief initial screen and the PHQ-9 as either a standalone screening tool or a more comprehensive follow-up for members who screen positive on the PHQ-2.<\/p>\n

The critical requirement is that the screening instrument and resulting score are documented accurately, ensuring plans can report results to CMS and remain audit-ready.<\/p>\n

Depression screening was among the first measure types NCQA built its Electronic Clinical Data Systems (ECDS) reporting standard around, specifically to capture patient-reported outcomes that don’t show up in claims.<\/p>\n

Case management systems and health risk assessments are both established, acceptable data sources under this standard, provided the screening uses a validated instrument like the PHQ-2 to PHQ-9 with the required data elements captured. Self-guided, digital completion fits squarely within this framework.<\/strong><\/p>\n

2. Follow-Up After Positive Screening<\/strong><\/p>\n

The second component is where most plans will face the greatest operational challenge: it measures the percentage of members who screen positive and receive documented follow-up within 30 days.<\/p>\n

Qualifying follow-up activities include:<\/p>\n